Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Manipulated Slow Release of Florfenicol Hydrogels for Effective Treatment of Anti-Intestinal Bacterial Infections.
Int J Nanomedicine
January 2025
Department of Clinical Pathology, Faculty of Veterinary Medicine, Benha University, Moshtohor, Toukh, 13736, Egypt.
Objective: The difficulty of establishing slow release at intestinal infection sites, weak antibacterial effects, as well as the limited broad use of florfenicol oral formulations are the main targets of the current study. Novel hydrogels derived from sodium alginate were developed using a complexation form for florfenicol delivery to achieve slow release at the site of intestinal infection and enhance its antibacterial activity against .
Methods: The optimal formulation, physicochemical properties, stability, pH-responsive performance, antibacterial activity, and in vitro biosafety of the florfenicol hydrogels have been studied systematically.
Assessment of anti-MRSA activity of auranofin and florfenicol combination: a PK/PD analysis.
J Appl Microbiol
December 2024
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Guangzhou, 510642, China.
Aims: Methicillin-resistant Staphylococcus aureus (MRSA) is an important zoonotic pathogen with multidrug-resistant phenotypes increasingly prevalent in both human and veterinary clinics. This study evaluated the potential of auranofin (AF) as an antibiotic adjuvant to enhance the anti-MRSA activity of florfenicol (FFC) and established a pharmacokinetic/pharmacodynamic (PK/PD) model to compare the efficacy of FFC alone or in combination with AF against MRSA.
Methods And Results: We observed an increased susceptibility and significant synergistic effects of MRSA to FFC in the presence of AF.
Pharmacokinetics of pradofloxacin, florfenicol, and tulathromycin and response to treatment of steers experimentally infected with Mannheimia hemolytica.
J Vet Intern Med
December 2024
Department of Molecular and Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Background: Bovine respiratory disease (BRD) is an economically important disease in the beef industry, and a major driver of therapeutic antibiotic use. Pharmacokinetic data of these drugs is relatively limited in diseased animals.
Hypothesis/objective: To determine the concentrations of pradofloxacin, florfenicol, and tulathromycin in the airways, plasma, and interstitial fluid (ISF) of steers with a clinically relevant model of bacterial respiratory disease.
Analysis of the Prevalence of Bacterial Pathogens and Antimicrobial Resistance Patterns of in Largemouth Bass () from Guangdong, China.
Pathogens
November 2024
Guangzhou Key Laboratory of Aquatic Animal Diseases and Waterfowl Breeding, Innovative Institute of Animal Healthy Breeding, College of Animal Sciences and Technology, Zhongkai University of Agriculture and Engineering, Guangzhou 510222, China.
To gain insights into the prevalence and antimicrobial resistance patterns of major bacterial pathogens affecting largemouth bass () in the Pearl River Delta (PRD) region, Guangdong, China, a study was conducted from August 2021 to July 2022. During this period, bacteria were isolated and identified from the internal organs of diseased largemouth bass within the PRD region. The antimicrobial resistance patterns of 11 antibiotics approved for use in aquaculture in China were analyzed in 80 strains of using the microbroth dilution method.
View Article and Find Full Text PDFComparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of and .
Molecules
November 2024
Department of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.
Pradofloxacin is a dual targeting, bactericidal fluoroquinolone recently approved for treating bacteria causing swine respiratory disease. Currently, an abundance of in vitro data does not exist for pradofloxacin. We determined the minimum inhibitory concentration (MIC) and mutant prevention concentrations (MPC) of pradofloxacin compared to ceftiofur, enrofloxacin, florfenicol, marbofloxacin, tildipirosin, tilmicosin and tulathromycin against swine isolates of and .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!